Literature DB >> 29249416

LncRNA GAS5-AS1 inhibits myofibroblasts activities in oral submucous fibrosis.

Che-Yi Lin1, Yi-Wen Liao2, Pei-Ling Hsieh3, Ming-Yi Lu4, Chih-Yu Peng4, Pei-Ming Chu5, Hui-Wen Yang4, Yu-Feng Huang4, Cheng-Chia Yu6, Chuan-Hang Yu7.   

Abstract

BACKGROUND/
PURPOSE: Emerging research findings suggest that long non-coding RNAs (lncRNAs) are key regulators to fibrosis formation. Nevertheless, the role of lncRNA GAS5-AS1 in the progression of precancerous oral submucous fibrosis (OSF) remains to be elucidated.
METHODS: Quantitative real-time PCR were used to examine the expression of GAS5-AS1 in OSF tissues. The activities of myofibroblasts, including collagen contractility and cell migration, as well as the marker α-smooth muscle actin (SMA) were assessed following overexpression of GAS5-AS1. Also, we analyzed the expression of Smad activity in order to gain insight into the downstream regulator.
RESULTS: The level of GAS5-AS1 was found significantly downregulated in the OSF tissues and fibrotic buccal mucosal fibroblasts (fBMFs). Ectopic expression of GAS5-AS1 significantly reduced the abilities of collagen gel contraction and migration in fBMFs or arecoline-treated BMFs. Moreover, we have shown that overexpression of GAS5-AS1 inhibited the expression of p-Smad and the marker of myofibroblasts.
CONCLUSION: We showed the reduced expression of GAS5-AS1 in OSF tissues and demonstrated its effect on the myofibroblast activities and the level of p-Smad and α-SMA, indicating its potential contribution in OSF pathogenesis.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Myofibroblasts; Oral submucous fibrosis; lncRNA GAS5-AS1

Mesh:

Substances:

Year:  2017        PMID: 29249416     DOI: 10.1016/j.jfma.2017.09.012

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  8 in total

Review 1.  Long non‑coding RNAs are novel players in oral inflammatory disorders, potentially premalignant oral epithelial lesions and oral squamous cell carcinoma (Review).

Authors:  Kaiying Zhang; Wei Qiu; Buling Wu; Fuchun Fang
Journal:  Int J Mol Med       Date:  2020-06-03       Impact factor: 4.101

2.  Tanshinone IIA promotes the apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis by up-regulating lncRNA GAS5.

Authors:  Guoqing Li; Ying Liu; Fanru Meng; Zhongbin Xia; Xia Wu; Yuxuan Fang; Chunwang Zhang; Dan Liu
Journal:  Biosci Rep       Date:  2018-10-05       Impact factor: 3.840

3.  LINC00312/YBX1 Axis Regulates Myofibroblast Activities in Oral Submucous Fibrosis.

Authors:  Chuan-Hang Yu; Chih-Yuan Fang; Cheng-Chia Yu; Pei-Ling Hsieh; Yi-Wen Liao; Lo-Lin Tsai; Pei-Ming Chu
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

4.  Targeting lncRNA H19/miR-29b/COL1A1 Axis Impedes Myofibroblast Activities of Precancerous Oral Submucous Fibrosis.

Authors:  Cheng-Chia Yu; Yi-Wen Liao; Pei-Ling Hsieh; Yu-Chao Chang
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

5.  Low LINC02147 expression promotes the malignant progression of oral submucous fibrosis.

Authors:  Jun Chen; Wenjie Li; Binjie Liu; Xiaoli Xie
Journal:  BMC Oral Health       Date:  2022-07-29       Impact factor: 3.747

Review 6.  Serum non-coding RNAs for diagnosis and stage of liver fibrosis.

Authors:  Chao Liu; Xueyun Hou; Kaixin Mo; Nannan Li; Cheng An; Guijian Liu; Zongdai Pan
Journal:  J Clin Lab Anal       Date:  2022-08-21       Impact factor: 3.124

7.  Adipose-Derived Stem Cell-Derived Extracellular Vesicles Inhibit the Fibrosis of Fibrotic Buccal Mucosal Fibroblasts via the MicroRNA-375/FOXF1 Axis.

Authors:  Bin Han; Yanhui Zhang; Yuxia Xiao; Bohong Shi; Hong Wu; Desheng Liu
Journal:  Stem Cells Int       Date:  2021-06-22       Impact factor: 5.443

Review 8.  Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments.

Authors:  Yen-Wen Shen; Yin-Hwa Shih; Lih-Jyh Fuh; Tzong-Ming Shieh
Journal:  Int J Mol Sci       Date:  2020-09-30       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.